At the PTAB Blog

At the PTAB Blog

Possible Defects Won’t Render Prior Art Inoperative Possible Defects Won’t Render Prior Art Inoperative

At the PTAB Blog

Dialing up Fixes to Your Patent Claims: So Relaxing! Dialing up Fixes to Your Patent Claims: So Relaxing!

At the PTAB Blog

Federal Circuit PTAB Appeal Statistics for October and November 2022 Federal Circuit PTAB Appeal Statistics for October and November 2022

At the PTAB Blog

The Power of Ordinary Skill: PTAB Denies Rehearing Request Based on the Defined POSA Lacking Skill to Support Obviousness Arguments The Power of Ordinary Skill: PTAB Denies Rehearing Request Based on the Defined POSA Lacking Skill to Support Obviousness Arguments

At the PTAB Blog

Claim Construction Can Be Determinative! Claim Construction Can Be Determinative!

At the PTAB Blog

Board Reaffirms that Assignor Estoppel Does Not Bar Assignor from Filing IPR Petition Board Reaffirms that Assignor Estoppel Does Not Bar Assignor from Filing IPR Petition

At the PTAB Blog

References Cited in IDSs but Not Discussed by Examiners May Get Petitioners over the Hurdle of Institution Denial References Cited in IDSs but Not Discussed by Examiners May Get Petitioners over the Hurdle of Institution Denial

At the PTAB Blog

Sometimes Better Never Than Late Sometimes Better Never Than Late

At the PTAB Blog

Inequitable Conduct Claim Can Proceed Even After the Case Is Over Inequitable Conduct Claim Can Proceed Even After the Case Is Over

At the PTAB Blog

Obviousness Allegations Fall Short After Petitioner’s “Weak Showing” of a Motivation to Combine the Art Obviousness Allegations Fall Short After Petitioner’s “Weak Showing” of a Motivation to Combine the Art

At the PTAB Blog

Single Value Found Not Inherently Anticipated or Inherently Obvious from a Range Single Value Found Not Inherently Anticipated or Inherently Obvious from a Range

At the PTAB Blog

Finnegan Attorneys Author the Third Edition of The Practitioner’s Guide to Trials Before the Patent Trial and Appeal Board Finnegan Attorneys Author the Third Edition of The Practitioner’s Guide to Trials Before the Patent Trial and Appeal Board

At the PTAB Blog

IPR, CBM, and PGR Statistics for PTAB Final Written Decisions Through September 2022 IPR, CBM, and PGR Statistics for PTAB Final Written Decisions Through September 2022

At the PTAB Blog

PTAB Denies IPR Challenging Patent Relating to a Prenatal Vitamin PTAB Denies IPR Challenging Patent Relating to a Prenatal Vitamin

At the PTAB Blog

Product-by-Process Construction Dooms Claims Product-by-Process Construction Dooms Claims

At the PTAB Blog

Updated PTAB Guidance on Use of Applicant Admitted Prior Art in IPRs Updated PTAB Guidance on Use of Applicant Admitted Prior Art in IPRs

At the PTAB Blog

Federal Circuit PTAB Appeal Statistics for September 2022 Federal Circuit PTAB Appeal Statistics for September 2022

At the PTAB Blog

Will the Real "Another" Please Stand Up? Will the Real "Another" Please Stand Up?

At the PTAB Blog

957 Salts Too Many to "At Once Envisage"; Mylan's Attacks on Patentability Peter Out 957 Salts Too Many to "At Once Envisage"; Mylan's Attacks on Patentability Peter Out

At the PTAB Blog

No Interference Estoppel to Zynga's IPR Petition No Interference Estoppel to Zynga's IPR Petition

At the PTAB Blog

Written Description Support Pre-AIA Scuttles PGR Written Description Support Pre-AIA Scuttles PGR

At the PTAB Blog

Want to Avoid Having Your Complaint Dismissed? Plead It with Sufficient Particularity and Don’t Take Positions Contrary to What You Told PTAB Want to Avoid Having Your Complaint Dismissed? Plead It with Sufficient Particularity and Don’t Take Positions Contrary to What You Told PTAB

At the PTAB Blog

Federal Circuit PTAB Appeal Statistics for July and August 2022 Federal Circuit PTAB Appeal Statistics for July and August 2022

At the PTAB Blog

PTAB Invalidates United Therapeutics Patent Relating to the Hypertension Drug - Tyvaso® PTAB Invalidates United Therapeutics Patent Relating to the Hypertension Drug - Tyvaso®

At the PTAB Blog

USPTO Director Initiates Sua Sponte Review to Address Timing of Finitiv Factor 4 Stipulation USPTO Director Initiates Sua Sponte Review to Address Timing of Finitiv Factor 4 Stipulation